These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9481721)

  • 1. Continuous intravenous intradialysis versus intravenous postdialysis erythropoietin therapy in chronic haemodialysis patients: a randomized, controlled, crossover study.
    Rocha JL; Gentil MA; Gili M; Gil L; Cabello V; Bernal G
    Nephrol Dial Transplant; 1998 Jan; 13(1):89-92. PubMed ID: 9481721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
    Allegra V; Martimbianco L; Vasile A
    Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2002; (4):CD003895. PubMed ID: 12519614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
    Lui SF; Wong KC; Li PK; Lai KN
    Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous erythropoietin administration in predialysis patients: a single centre prospective study.
    Branger B; Vécina F; Zabadani B; Balducchi JP; Fourcade J
    Nephrol Dial Transplant; 1995; 10 Suppl 6():36-9. PubMed ID: 8524492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.).
    De Schoenmakere G; Lameire N; Dhondt A; Van Loo A; Van der Goten J; Duym P; Vanholder R
    Nephrol Dial Transplant; 1998 Jul; 13(7):1770-5. PubMed ID: 9681726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients.
    Albitar S; Meulders Q; Hammoud H; Soutif C; Bouvier P; Pollini J
    Nephrol Dial Transplant; 1995; 10 Suppl 6():40-3. PubMed ID: 8524493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
    Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
    Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correction of anemia in chronic kidney failure with lyophilized recombinant human erythropoietin using a subcutaneous approach].
    Amar M; Cendoroglo Neto M; Canziani ME; Nadaletto MA; Ajzen H; Draibe SA
    Rev Assoc Med Bras (1992); 1994; 40(2):101-7. PubMed ID: 7820145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human erythropoietin on synthesis of methylguanidine in uraemic patients on haemodialysis or continuous ambulatory peritoneal dialysis.
    Sasagawa I; Nakada T; Kubota Y; Sawamura T; Suzuki H; Hashimoto T
    Int Urol Nephrol; 1994; 26(6):701-5. PubMed ID: 7759207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia and carnitine supplementation in hemodialyzed patients.
    Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
    Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acetate-free biofiltration on the anaemia of haemodialysis patients: a prospective cross-over study.
    Basile C; Giordano R; Montanaro A; De Maio PD; De Padova FD; Marangi AL; Semeraro A
    Nephrol Dial Transplant; 2001 Sep; 16(9):1914-9. PubMed ID: 11522879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
    Albitar S; Genin R; Fen-Chong M; Serveaux MO; Bourgeon B
    Nephrol Dial Transplant; 1998 May; 13(5):1206-10. PubMed ID: 9623555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
    Del Vecchio L; Villa G; Carraro G; Morosetti M; Pedrini L; Adorati Menegato M; Amato M; Mauro MM; Borgatti P; Malberti F; Marai P; Locatelli F;
    G Ital Nefrol; 2004; 21(3):259-66. PubMed ID: 15285005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.